Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Tumor-Suppressive Cross-Linking of Anti-T. cruzi Antibodies in Acute Lymphoblastic Leukemia

Víctor Alberto Maravelez Acosta 1María del Pilar Crisóstomo Vázquez 1Leticia Eligio García 1Luz Ofelia Franco Sandoval 1Denia Castro Pérez 1Genaro Patiño López 2Oscar Medina Contreras 3Enedina Jiménez Cardoso 1,*



Abstract

Parasites have been associated with possible anticancer activity, including Trypanosoma cruzi, which has been linked to inhibiting the growth of solid tumors. To better understand this antitumor effect, we investigated the association of anti-T. cruzi antibodies with B cells of the acute lymphoblastic leukemia (ALL) SUPB15 cell line. The antibodies were generated in rabbits. IgGs were purified by affinity chromatography. Two procedures (flow cytometry (CF) and Western blot(WB)) were employed to recognize anti-T. cruzi antibodies on SUPB15 cells. We also used CF to determine whether the anti-T. cruzi antibodies could suppress SUPB15 cells. The anti-T. cruzi antibodies recognized 35.5% of the surface antigens of SUPB15. The complement-dependent cytotoxicity (CDC) results demonstrate the cross-suppression of anti-T. cruzi antibodies on up to 8.4% of SUPB15 cells. For the WB analysis, a band at 100 kDa with high intensity was sequenced using mass spectrometry, identifying the protein as nucleolin. This protein may play a role in the antitumor effect on T. cruzi. The anti-T. cruzi antibodies represent promising polyclonal antibodies that have the effect of tumor-suppressive cross-linking on cancer cells, which should be further investigated.

We confirmed the presence of nucleolin in the plasma membrane of SUPB15. Immunostaining with a mouse monoclonal antibody specific for nucleolin (clone: NCL/902, NeoBiotechnologies, cat. 4691-MSM1-P1) followed by Alexa Fluor 647-conjugated secondary antibody revealed the presence of nucleolin on the plasma membrane of 37.7% of SUPB15 (Figure 5b). CF was analyzed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) and FlowJo v10.0.7 software (Tree Star, Ashland, OR, USA). These findings provide evidence for nucleolin’s localization to SUPB15 plasma membrane.


Publication History:
Int J Mol Sci. 2024 Jul 30;25(15):8307. doi: 10.3390/ijms25158307

Footnotes:
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK